Despite facing various challenges, including clinical trial complexities, lengthy approval processes, and regulatory hurdles, the biotech industry thrives due to consistent innovations and sustained demand for quality drugs and therapies.
Therefore, investors could consider waiting for a better entry point in Moderna, Inc. (MRNA). On the other hand, given its poor fundamentals and growth prospects, Arrowhead Pharmaceuticals, Inc. (ARWR) is best avoided.
